28
Participants
Start Date
December 10, 2018
Primary Completion Date
April 27, 2022
Study Completion Date
March 18, 2025
Talimogene laherparepvec
Talimogene laherparepvec will be given via intra-tumoral injection at an initial dose of 10\^6 PFU/mL. On week 3 (i.e. 21 days \[± 2\] days), a second talimogene laherparepvec injection will be administered at a dose of 10\^8 PFU/mL. Third, fourth and fifth injections will be administered every 2 weeks (every 14 \[± 2\] days). The maximum volume for each injection will be 4.0 mL.
Atezolizumab
Atezolizumab 840 mg will be administered by IV infusion on Day1 week 3, then every 2 weeks (every 14 \[± 2\] days), for a total of 4 treatment courses.
Centro Integral Oncológico Clara Campal, Madrid
Hospital Clínico universitario de Valencia, Valencia
Hospital Universitari Vall d'Hebrón, Barcelona
Hospital Clínic de Barcelona, Barcelona
Collaborators (1)
Amgen
INDUSTRY
Roche Pharma AG
INDUSTRY
SOLTI Breast Cancer Research Group
OTHER